Factors affecting nodal status in invasive breast cancer: A retrospective analysis of 623 patients

Breast Journal

Volumn 16, Issue 3, 2010, Pages 271-278

  Aitken, Emma ^a   Osman, Monzir ^a  

^a CROSSHOUSE HOSPITAL   (United Kingdom)

Author keywords

Axillary node clearance; Breast cancer; Lymph nodes; Sentinel node biopsy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; AGING; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER INVASION; CANCER SURGERY; FEMALE; HISTOLOGY; HUMAN; LYMPH NODE METASTASIS; LYMPH VESSEL; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; MASTECTOMY; MENOPAUSE; RETROSPECTIVE STUDY; TUMOR VOLUME; BREAST TUMOR; LYMPH NODE; MIDDLE AGED; PATHOLOGY; SENTINEL LYMPH NODE BIOPSY; TUMOR INVASION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM INVASIVENESS; RETROSPECTIVE STUDIES; SENTINEL LYMPH NODE BIOPSY;

EID: 77953599288     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2009.00897.x     Document Type: Article

References (37)

1. Rosen PP, Groshen S. Factors influencing survival and prognosis in early breast carcinoma (T1N0M0-T1N1M0). Assessment of 644 patients with median follow-up of 18 years. Surg Clin North Am 1990;70:937-962
2. Mustafa IA, Cole B, Wanebo HJ, Bland KI, Chang HR. Prognostic analysis of survival in small breast cancers. J Am Coll Surg 1998;186:562-569
3. Veronesi U, Luini A, Galimberti V, Marchini S, Sacchinin V, Rilke F. Extent of metastatic axillary involvement in 1446 cases of breast cancer. EJSO 1990;16:127-133
4. Veronesci U, Galimberti V, Zurrida S, Merson M, Greco M, Luinin A. Prognostic significance of number and level of axillary node metastases in breast cancer. The Breast 1993;2:224-228
5. Pandelidis SM, Peters KL, Walusimbi MS, et al. The role of axillary dissection in mammographically detected carcinoma. J Am Coll Surg 1997;184:1-3.
6. Tan LGL, Tan YY, Heng D, Chan MY. Predictors of axillary lymph node metastases in women with early breast cancer in Singapore. Singapore Med J 2005;46:693-697
7. Scottish Intercollegiate Guidelines Network (SIGN) Guideline 84: Management of breast cancer in women, NHS Quality Improvement, Edinburgh, Scotland 2005
8. Aitken RJ, Gaze MN, Rodger A, Chetty U, Forrest APM. Arm morbidity within a trial of mastectomy and either nodal sample with elective radiotherapy or axillary clearance. Br J Surg 1989;76:568-571
9. Bundred NJ, Morgan DAL, Dixon JM. ABC of breast diseases: management of regional nodes in breast cancer. BMJ 1994;309:1222-1225
10. Harden SP, Neal AJ, Al-Nasiri N, Ashley S, Querci della Rovere G. Predicting axillary lymph node metastases in patients with T1 infiltrating ductal carcinoma of the breast. The Breast 2001;10:155-159
11. Cady B. The need to re-examine axillary lymph node dissection in invasive breast cancer. Cancer 1994;73:505-508
12. Rivadeneria DE, Simmons RM, Christos PJ, Hanna K, Daly DE, Osborne C. Predictive factors associated with axillary lymph node metastases in T1a and T1b breast carcinomas. J Am Coll Surg 2000;191:1-6.
13. Gill PG, Luke CG, Roder DM. Clinical and pathological factors predictive of lymph node status in women with screendetected breast cancer. The Breast 2006;15:640-648
14. Jatio I. Management of the axilla in primary breast cancer. Surg Clin North Am 1999;79:1061-1073
15. Lin PP, Allison DC, Wainstock J, et al. Impact of axillary lymph node dissection on the therapy of breast cancer patients. J Clin Oncol 1993;11:1536-1544
16. Deckers PJ. Axillary dissection in breast cancer: when, why, how much and for how long? Another operation soon to be extinct? J Surg Oncol 1991;48:217-219
17. Cady B, Stone MD, Schuler JG. The new era in breast cancer: invasion, size and nodal involvement dramatically decreasing as a result of mammographic screening. Arch Surg 1996;131: 301-308
18. Silverstein MJ, Gierson ED, Waisman JR, Senofysky GM, Colburn WJ, Gamagami P. Axillary lymph node dissection for T1a breast carcinoma: is it indicated? Cancer 1994;73:664-667
19. Kissin WM, Thompson EM, Price AM, et al. The inadequacy of axillary sampling in breast cancer. Lancet 1982;1: 1210-1212
20. Forrest APM, Stewart HJ, Roberts MM, Steele RJC. Simple mastectomy and axillary node sampling in the management of primary breast cancer. Am J Surg 1982;196:371-378
21. Edwards MJ, Whitworth P, Tafra L, McMasters KM. The details of successful sentinel lymph node staging for breast cancer. Am J Surg 2000;180:257-261
22. Goyal A, Newcombe R, Chhabra A, Mansel R. Factors affected failed localisation and false negative rates of sentinel node biopsy in breast cancer- results of the ALMANAC validation phase. Breast Cancer Res Treat 2006;99:203-208
23. Rivers A, Hansen N. Axillary management after sentinel lymph node biopsy in breast cancer patients. Surg Clin North Am 2007;87:365-377
24. Mansel R, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial. J Natl Cancer Inst 2006;98:599-609.
25. Kamath VJ, Guiliano R, Dauway EL, et al. Characteristics of the sentinel lymph node in breast cancer predict further involvement of higher-echelon nodes in the axilla: a study to evaluate the need for complete axillary lymph node dissection. Arch Surg 2001;136:688-698
26. Rahusen FD, Torrenga H, van Diest PJ, et al. Predictive factors for metastatic involvement of non-sentinel nodes in patients with breast cancer. Arch Surg 2001;136:1059-1063
27. Wada N, Imoto S, Yamauchi C, Hasebe T, Ochiai A. Predictors of tumour involvement in remaining axillary lymph nodes of breast cancer patients with positive sentinel lymph node. EJSO 2006;32:29-33.
28. Zgajnar J, Hocevar M, Podkrajsek M, et al. Patients with preoperatively ultrasonically uninvolved axillary lymph nodes: a distinct subgroup of early breast cancer patients. Breast Cancer Res Treat 2006;97:293-299
29. Skinner KA, Silberman H, Sposto R, Silverstein MJ. Palpable breast cancers are inherently different from non-palpable breast cancers. Ann Surg Oncol 2001;8:1530-1536
30. Fein DA, Fowble BL, Hanlon AL, et al. Identification of women with T1-T2 breast cancer at low risk of positive axillary nodes. J Surg Oncol 1997;65:34-39
31. Barth A, Craig PH, Silverstein MJ. Predictors of axillary lymph node metastases in patients with T1 breast carcinoma. Cancer 1997;79:1918-1922 (Pubitemid 27200375)
32. Chua B, Ung O, Taylor R, et al. Frequency and predictors of axillary lymph node metastases in invasive breast cancer. ANZ J Surg 2001;71:723-728
33. Bevilacqua JLB, Cody HS, MacDonald KA, Tan LK, Borgen PI, van Zee KJ. A model for predicting axillary node metastases on 2000 sentinel node procedures and tumour position. EJSO 2002;28:490-500.
34. Viale G, Zurrida S, Maiorano E, et al. Predicting the status of axillary sentinel lymph nodes in 4351 patients with invasive breast carcinoma treated in a single institution. Cancer 2005;103:492-500.
35. Nixon AJ, Schnitt SJ, Gelman R, et al. Relationship of tumour grade to other pathologic features and to treatment outcome of patients with early stage breast carcinoma treated with breastconserving therapy. Cancer 1996;78:1426-1431
36. Mustafa IA, Cole B, Wanebo HJ, et al. The impact of histopathology on nodal metastases in minimal breast cancer. Arch Surg 1997;132:384-391
37. Olivotto IA, Jackson JS, Mates D, et al. Prediction of axillary lymph node involvement of women with invasive breast carcinoma: a multivariate analysis. Cancer 1998;83:948-955